Reprogramming the immune system: a new strategy against ovarian cancer

By Elodie Vaz | Published on March 16, 2026 | 3 min read  


Ovarian cancer remains one of the most feared gynecological cancers, largely due to late diagnosis and a strong tendency to develop therapeutic resistance. The most common and aggressive form is high-grade serous ovarian cancer, which often responds initially to chemotherapy but frequently becomes refractory to treatment over time.  

While immunotherapies, particularly immune checkpoint inhibitors, have transformed the management of several solid tumors, their effectiveness in ovarian cancer has been limited. One major reason is that cancer cells actively reshape their immune microenvironment, weakening the body's immune response and enabling tumors to evade immune attack.  

In this context, a study conducted by researchers at the University of California San Diego and published in the journal Cell in March 2026 proposes a new therapeutic strategy aimed at reprogramming the interaction between tumors and the immune system.  

Understanding how to reverse tumor-induced immunosuppression  

The objective of this research was to identify molecular mechanisms capable of modifying communication between ovarian tumor cells and surrounding immune cells in order to restore an effective immune response.  

The researchers focused on a key intracellular protein: focal adhesion kinase (FAK). This kinase is frequently highly activated in ovarian cancers and plays an important role in tumor progression.  

According to David D. Schlaepfer, senior author of the study and professor at the UC San Diego School of Medicine, “our results reveal a previously unknown lipid communication pathway between ovarian tumors and the immune system.” He adds that “by inhibiting FAK, we can reprogram macrophages so that they promote antitumor immunity rather than suppress it.”  

An experimental approach focused on cellular communication

To investigate this mechanism, the researchers studied the consequences of blocking FAK activity in ovarian tumor cells and examined how this inhibition affected surrounding immune cells.  

They analyzed the molecular signals produced by tumor cells and how these signals were detected by macrophages, key immune cells involved in regulating inflammatory and immune responses.  

Murine models of ovarian cancer were also used to evaluate the therapeutic impact of a strategy combining FAK inhibition, low-dose chemotherapy, and immunotherapy.  

Macrophages reprogrammed as antitumor allies  

The results showed that blocking FAK activity in tumor cells profoundly alters their communication with the immune system. Under these conditions, cancer cells release small lipid particles rich in omega-3 fatty acids, similar to those found in fish oil.  

These particles are taken up by nearby macrophages, which interpret these lipids as cellular signals. In response, macrophages adopt an antitumor phenotype and begin producing the molecule CXCL13.  

CXCL13 acts as a chemotactic signal that attracts additional immune cells capable of attacking cancer cells, thereby increasing immune infiltration within the tumor microenvironment.  

In mouse models, the combination of a FAK inhibitor, low-dose chemotherapy, and immunotherapy suppressed tumor growth, increased immune cell infiltration, and prolonged survival.  

A promising therapeutic strategy  

These findings highlight a previously unknown mechanism linking tumor lipid metabolism and immune microenvironment reprogramming. By transforming macrophages from an immunosuppressive role to an immune-activating role, FAK inhibition could overcome one of the major barriers to effective immunotherapy in ovarian cancer.  

Drugs targeting FAK are already being evaluated in clinical trials for ovarian cancer. The results of this study suggest that combining these agents with certain chemotherapies and immunotherapies could significantly improve therapeutic responses. Although further research and clinical trials are required, this strategy opens the door to a new generation of treatments aimed not only at targeting the tumor itself but also at reshaping its immune microenvironment. Such an approach could ultimately benefit patients with ovarian cancer and potentially other cancers characterized by strong tumor-induced immunosuppression.

Read next: TyG Index: a new ally against PCOS?

About the Author – Elodie Vaz
Health journalist, CFPJ graduate (2023).
Élodie explores the marks diseases leave on bodies and, more broadly, on human life. A registered nurse since 2010, she spent twelve years at patients’ bedsides before exchanging her stethoscope for a notebook. She now investigates the links between environment and health, convinced that the vitality of life cannot be reduced to that of human.